{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:15:18Z","timestamp":1789172118016,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100019507","name":"Ortho Dermatologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Onychomycosis is common in older adults and can be difficult to treat owing to slower nail growth, increased nail thickness, comorbidities, and concomitant medications. Oral treatments can be complicated by contraindications, drug\u2013drug interactions, and adverse effects. Topical treatments such as efinaconazole 10% solution may be beneficial for treating older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy\/safety of efinaconazole 10% solution in adults aged \u2265\u200965\u2009years with toenail onychomycosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/Methods<\/jats:title>\n                    <jats:p>\n                      In two multicenter, double\u2010blind, phase 3 studies (NCT01008033; NCT01007708), patients with mild to moderate toenail onychomycosis were randomised (3:1) to once\u2010daily efinaconazole or vehicle for 48\u2009weeks, with a 4\u2010week follow\u2010up. Pooled data for participants aged \u2265\u200965\u2009years were analysed post hoc (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009162 efinaconazole,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956 vehicle). The primary endpoint was complete cure (0% involvement of target toenail plus mycologic cure [negative KOH and fungal culture]) at week 52. Treatment\u2010emergent adverse events (TEAEs) were assessed throughout.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 52, a significantly greater proportion of older adults (aged 65\u201371\u2009years) achieved complete cure with efinaconazole than vehicle (13.6% vs. 3.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Complete\/almost complete cure rate was also significantly greater (\u2264\u20095% involvement and mycologic cure; 19.1% vs. 5.4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and over half (59.2%) of participants achieved mycologic cure with efinaconazole versus 12.5% with vehicle (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Treatment\u2010related TEAE rates with efinaconazole were low (6.0%) and similar to the overall study population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Efinaconazole 10% solution showed similar efficacy\/safety in participants aged \u2265\u200965\u2009years to the overall phase 3 population, despite potential age\u2010related nail changes. These results demonstrate the benefits of efinaconazole in older patients with onychomycosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/myc.70069","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T06:20:23Z","timestamp":1747808423000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"},{"name":"Division of Dermatology, Temerty Faculty of Medicine, Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren S.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Arizona College of Podiatric Medicine Midwestern University  Glendale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni","family":"Elewski","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham School of Medicine  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guenin","sequence":"additional","affiliation":[{"name":"Ortho Dermatologics, a division of Bausch Health US, LLC  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey C.","family":"Vlahovic","sequence":"additional","affiliation":[{"name":"Samuel Merritt University College of Podiatric Medicine  Oakland California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6291"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof4030087"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S362635"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S72701"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010021\u201000917\u20108"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2009.03487.x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2336989"},{"issue":"1","key":"e_1_2_12_9_1","first-page":"58","article-title":"Efinaconazole Topical Solution, 10%: The Benefits of Treating Onychomycosis Early","volume":"14","author":"Rich P.","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.019"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof9070712"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2014.14090"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13683"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v8i2.656"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S431526"},{"key":"e_1_2_12_16_1","unstructured":"\u201cSporanox\u00ae(Itraconazole Oral Tablets) \u201dFull Prescribing Information Stiefel Laboratories Inc. (2010)."},{"key":"e_1_2_12_17_1","unstructured":"\u201cLamisil\u00ae(Terbinafine Hydrochloride Oral Tablets) \u201dFull Prescribing Information Novartis Pharmaceuticals Corp. (2019)."},{"key":"e_1_2_12_18_1","unstructured":"\u201cDiflucan\u00ae(Fluconazole Oral Tablets) \u201dFull Prescribing Information Pfizer Inc. (2011)."},{"key":"e_1_2_12_19_1","unstructured":"\u201cGris\u2010Peg\u00ae(Griseofulvin Ultramicrosize Oral Tablets) \u201dFull Prescribing Information Valeant Pharmaceuticals North America LLC (2016)."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20104\u201050"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2005.12.012"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20104362.2000.00087\u20102.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.110874"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.14607"},{"issue":"4","key":"e_1_2_12_26_1","first-page":"299","article-title":"Safety and Tolerability of Oral Antifungal Agents in the Treatment of Fungal Nail Disease: A Proven Reality","volume":"1","author":"Elewski B.","year":"2005","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof9050559"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.010"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"issue":"7","key":"e_1_2_12_30_1","first-page":"815","article-title":"The Efficacy and Safety of Efinaconazole 10% Solution for Treatment of Mild to Moderate Onychomycosis: A Pooled Analysis of Two Phase 3 Randomized Trials","volume":"13","author":"Gupta A. K.","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"issue":"7","key":"e_1_2_12_31_1","first-page":"694","article-title":"Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%","volume":"14","author":"Bhatia N.","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_12_32_1","first-page":"197","article-title":"Evaluation of Gender as a Clinically Relevant Outcome Variable in the Treatment of Onychomycosis With Efinaconazole Topical Solution 10%","volume":"96","author":"Rosen T.","year":"2015","journal-title":"Cutis"},{"issue":"4","key":"e_1_2_12_33_1","first-page":"286","article-title":"Efinaconazole Solution 10% for Treatment of Toenail Onychomycosis in Latino Patients","volume":"99","author":"Cook\u2010Bolden F. E.","year":"2017","journal-title":"Cutis"},{"issue":"2","key":"e_1_2_12_34_1","first-page":"42","article-title":"Onychomycosis of Toenails and Post\u2010Hoc Analyses With Efinaconazole 10% Solution Once\u2010Daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes","volume":"9","author":"Del Rosso J. Q.","year":"2016","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"10","key":"e_1_2_12_35_1","first-page":"1186","article-title":"Efinaconazole Topical, 10% for the Treatment of Toenail Onychomycosis in Patients With Diabetes","volume":"13","author":"Vlahovic T. C.","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1004"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.14935"},{"issue":"1","key":"e_1_2_12_38_1","first-page":"5","article-title":"Long\u2010Term Efficacy and Safety of Once\u2010Daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis","volume":"26","author":"Gupta A. K.","year":"2021","journal-title":"Skin Therapy Letter"},{"key":"e_1_2_12_39_1","unstructured":"\u201cKerydin\u00ae(Tavaborole Topical Solution) \u201dFull Prescribing Information Pfizer Inc. (2018)."},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00111\u201014"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010024\u201001237\u20106"},{"issue":"12","key":"e_1_2_12_42_1","first-page":"1269","article-title":"Long\u2010Term Follow\u2010Up of Onychomycosis Patients Treated With Efinaconazole","volume":"16","author":"Pollak R. A.","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1939011"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.70069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:58:25Z","timestamp":1789171105000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.70069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/myc.70069"],"URL":"https:\/\/doi.org\/10.1111\/myc.70069","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2025-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70069"}}